This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Dr. Barry Ticho, MD, PhD
Chief Medical Officer at Stoke Therapeutics
Speaker

Profile

Barry Ticho is the chief medical officer at Stoke Therapeutics, where he is helping to lead the company’s efforts to develop first-in-class therapeutics to treat rare diseases. Prior to joining Stoke, Barry was most recently head of development of mRNA treatments for cardiovascular and metabolic diseases at Moderna Therapeutics. Before Moderna, he was head of external R&D innovation for cardiovascular and metabolic diseases at Pfizer, and before that, he was vice president of clinical development at Biogen. Barry obtained his M.D. and Ph.D. degrees from the University of Chicago. He completed pediatrics training at Northwestern University and a cardiology fellowship at Boston Children’s Hospital. Barry has also served as a member of the clinical staff at Harvard Medical School and Massachusetts General Hospital, where he conducted laboratory research on the regulation of cardiac development.

Agenda Sessions

  • Protein Upregulation Via Antisense Oligonucleotide, A Potential Disease-Modifying Medicine For A Genetic Epilepsy

    9:00am